Publication
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMelanomacivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600civic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantBRAF V600Kcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22663011
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V6001 | ||||||||
| Trametinib | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1750Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E m… (full text at CIViC) PMID 22663011 · Flaherty et al., 2012 · Open in CIViC | civic |
| BRAF V600E1 | ||||||||
| Trametinib | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID2135In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8m… (full text at CIViC) PMID 22663011 · Flaherty et al., 2012 · Open in CIViC | civic |
| BRAF V600K1 | ||||||||
| Trametinib | Melanoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2506In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8m… (full text at CIViC) PMID 22663011 · Flaherty et al., 2012 · Open in CIViC | civic |